Hudson Bay Capital Management
SABS icon

Hudson Bay Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Hudson Bay Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.7K Buy
+16,100
New +$64.2K ﹤0.01% 1228
2021
Q4 		– Sell
-50,000
Closed -$5.04M – 1190
2021
Q3 		$5.04M Hold
50,000
– – 0.07% 325
2021
Q2 		$4.99M Hold
50,000
– – 0.06% 336
2021
Q1 		$4.91M Buy
+50,000
New +$5M 0.06% 296

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Hudson Bay Capital Management's SABS Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 16,100 shares worth $61.7K. The stake represents ﹤0.01% of the portfolio and ranks #1228 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in SABS as recently as Q3 2021.

Hudson Bay Capital Management first reported a position in SABS in Q1 2021 and has held it in 4 quarters since. The position peaked at $5.04M in Q3 2021. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Hudson Bay Capital Management held 16,100 shares of SAB Biotherapeutics worth $61.7K as of Q1 2026.
  • SAB Biotherapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1228 holding.
  • Hudson Bay Capital Management first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 4 quarters since.
  • Hudson Bay Capital Management's SAB Biotherapeutics position peaked at $5.04M in Q3 2021.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.